ArticleFrontiers in oncology2025
Association between the red cell distribution width-to-albumin ratio and recurrence-free survival and overall survival in patients with non-muscle-invasive bladder cancer: a retrospective cohort study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic utility of the red cell distribution width-to-albumin ratio (RAR) in non-muscle-invasive bladder cancer (NMIBC) has not been established. This study aimed to evaluate the associations between preoperative RAR and both recurrence-free survival (RFS) and overall survival (OS) in patients with NMIBC. Methods: A retrospective review was performed for 240 individuals with NMIBC having undergone transurethral resection of bladder tumor (TURBT) at Shijiazhuang People's Hospital from November 2013 to January 2024. Demographic characteristics, hematological parameters, pathological data, and information on instillation therapy were collected. The optimal RAR cutoff was identified by applying receiver operating characteristic (ROC) analysis. Survival curves were generated via the Kaplan-Meier method. The relationships of RAR with both RFS and OS were examined using univariate and multivariate Cox proportional hazards regression models. A nomogram was created using the identified independent prognostic factors from multivariate analysis to predict RFS. The discriminative ability and clinical usefulness of the nomogram were assessed by the concordance index (C-index), the calibration plots, time-dependent ROC analysis, and decision curve analysis (DCA). Results: Patients with higher preoperative RAR showed significantly poorer RFS and OS. Multivariate analysis identified high RAR as an independent prognostic factor for both RFS (HR: 1.731, 95% CI: 1.012 - 2.959) and OS (HR: 3.425, 95% CI: 1.196 - 9.806) in NMIBC patients. Based on these findings, RAR was incorporated into a nomogram model for predicting RFS. Compared to the baseline model without RAR, the new model exhibited an improved C-index (from 0.704 to 0.728). The calibration plots demonstrated excellent consistency of the nomogram-predicted probabilities for 1-, 3-, and 5-year RFS with the actual survival rates. The time-dependent ROC analysis revealed that the areas under the curve (AUC) values for RFS predictions at 1-, 3-, and 5- years were 0.806, 0.797 and 0.806. DCA validated that the nomogram yielded a superior net benefit within threshold probability ranges of 10% to 45% when compared to traditional staging systems. Conclusions: The findings suggest that preoperative RAR serves as a novel and independent prognostic factor for predicting RFS and OS in NMIBC cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.